Jacroux Richard 4

What Happened Richard Jacroux, Chief Financial Officer of ENDRA Life Sciences (NDRA), received an award of 20,000 restricted stock units (RSUs) on January 21, 2026. The RSUs were granted at $0.00 (no cash paid) and thus have no immediate cash purchase value; they represent a future entitlement to 20,000 common shares on a one-for-one basis once vested.

Key Details

• Transaction date: 2026-01-21; reported on Form 4 filed 2026-01-23 (timely filing).
• Transaction type/code: Award/Grant (A).
• Shares granted: 20,000 RSUs; grant price reported as $0.00 (no cash paid).
• Shares owned after transaction: Not specified in the filing.
• Footnote: RSUs convert one-for-one into common stock and will vest in full on January 21, 2027 (Footnote F1).
• Filing timeliness: Filed within two business days of the transaction date (not marked late).

Context RSUs are a form of equity compensation that convert to actual shares only upon vesting; they are not an open-market purchase and therefore do not directly signal a current purchase-based endorsement of the company. Once these RSUs vest (Jan 21, 2027), they will convert to common shares and may be subject to tax withholding or holding restrictions at that time.